Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gyobfe.2005.03.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HER2 Antibody-Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor.
Clin Cancer Res
October 2024
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Purpose: Desmoplastic small round cell tumor (DSRCT) is a rare but highly aggressive soft tissue sarcoma that arises in the abdominopelvic cavity of young males. Since the discovery of EWSR1::WT1 fusion as the driver of DSRCT, no actionable genomic alterations have been identified, limiting disease management to a combination of surgery, chemotherapy, and radiation, with very poor outcomes. Herein, we evaluated ERBB2/HER2 expression in DSRCT as a therapeutic target.
View Article and Find Full Text PDFTrastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
Eur J Cancer
May 2024
Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands. Electronic address:
Article Synopsis
- * Out of 24 patients, 46% showed clinical benefit, with a significant number achieving an objective response, and the overall treatment was considered safe with no unexpected side effects.
- * Whole genome sequencing helped identify potential resistance reasons in some patients, reinforcing the clinical significance of targeted therapy for HER2+mCRC.
Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.
J Exp Clin Cancer Res
February 2024
Department of Medical Oncology, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.
Background: The inability to predict treatment response of colorectal cancer patients results in unnecessary toxicity, decreased efficacy and survival. Response testing on patient-derived organoids (PDOs) is a promising biomarker for treatment efficacy. The aim of this study is to optimize PDO drug screening methods for correlation with patient response and explore the potential to predict responses to standard chemotherapies.
View Article and Find Full Text PDFImplementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care.
JCO Precis Oncol
December 2022
New York Genome Center; Department of Pathology, Columbia University Irving Medical Center, New York, NY.
Article Synopsis
- The combination of whole-genome and transcriptome sequencing (WGTS) holds the potential to revolutionize how cancer is diagnosed and treated by providing a more precise and comprehensive testing method compared to traditional approaches.
- Despite its promise, there are significant challenges in integrating WGTS into mainstream healthcare, including issues of cost-effectiveness, affordability, and regulatory concerns.
- Current research highlights the clinical evidence supporting WGTS while emphasizing the need for better implementation strategies to enhance its use in various cancer types and improve patient outcomes.
A single low-dose rituximab infusion in severe chronic refractory myasthenia gravis in resource-limited settings.
J Neurol Sci
November 2022
Neurology Division, Department of Medicine, Health Sciences Faculty, University of Cape Town, Cape Town, South Africa. Electronic address:
The benefits of multi-dose rituximab cycles in patients with refractory anti-muscle-specific kinase antibody myasthenia gravis (MuSK+MG) are well reported, although less consistently in anti-acetylcholine receptor antibody MG (AChR+MG). Responsivity data to single low-dose rituximab infusions for refractory autoimmune myasthenia, are limited. Here, observational outcomes using MG grading scores and prednisone doses, before and after at least six months of a single-dose infusion of rituximab, were audited in previously treatment-refractory MG patients in a resource-limited setting.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!